These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 12520524)
1. Vitamin D and bone. Suda T; Ueno Y; Fujii K; Shinki T J Cell Biochem; 2003 Feb; 88(2):259-66. PubMed ID: 12520524 [TBL] [Abstract][Full Text] [Related]
2. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. Ueno Y; Shinki T; Nagai Y; Murayama H; Fujii K; Suda T J Cell Biochem; 2003 Oct; 90(2):267-77. PubMed ID: 14505343 [TBL] [Abstract][Full Text] [Related]
3. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054 [TBL] [Abstract][Full Text] [Related]
4. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity. Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309 [TBL] [Abstract][Full Text] [Related]
5. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941 [TBL] [Abstract][Full Text] [Related]
6. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398 [TBL] [Abstract][Full Text] [Related]
7. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833 [TBL] [Abstract][Full Text] [Related]
8. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. Ishida M; Amano S J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862 [TBL] [Abstract][Full Text] [Related]
9. Activation of protease-activated receptor-2 leads to inhibition of osteoclast differentiation. Smith R; Ransjö M; Tatarczuch L; Song SJ; Pagel C; Morrison JR; Pike RN; Mackie EJ J Bone Miner Res; 2004 Mar; 19(3):507-16. PubMed ID: 15040840 [TBL] [Abstract][Full Text] [Related]
10. Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. Shibata T; Shira-Ishi A; Sato T; Masaki T; Masuda A; Hishiya A; Ishikura N; Higashi S; Uchida Y; Saito MO; Ito M; Ogata E; Watanabe K; Ikeda K J Bone Miner Res; 2002 Apr; 17(4):622-9. PubMed ID: 11918219 [TBL] [Abstract][Full Text] [Related]
11. Novel vitamin D3 analogs, 1alpha, 25(OH)2D(3)-26, 23-lactam (DLAMs), antagonize bone resorption via suppressing RANKL expression in osteoblasts. Inada M; Tsukamoto K; Hirata M; Takita M; Nagasawa K; Miyaura C Biochem Biophys Res Commun; 2008 Aug; 372(3):434-9. PubMed ID: 18489902 [TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085 [TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Uchiyama S; Yamaguchi M Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845 [TBL] [Abstract][Full Text] [Related]
14. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766 [TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the cytokine pattern of porcine bone marrow-derived cells treated with 1alpha,25(OH)D. Sipos W; Duvigneau JC; Schmoll F; Exel B; Hofbauer G; Baravalle G; Hartl RT; Dobretsberger M; Pietschmann P J Vet Med A Physiol Pathol Clin Med; 2005 Oct; 52(8):382-7. PubMed ID: 16176565 [TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921 [TBL] [Abstract][Full Text] [Related]
18. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Kaji H; Kanatani M; Sugimoto T; Chihara K Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780 [TBL] [Abstract][Full Text] [Related]
19. Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter. Kitazawa S; Kajimoto K; Kondo T; Kitazawa R J Cell Biochem; 2003 Jul; 89(4):771-7. PubMed ID: 12858342 [TBL] [Abstract][Full Text] [Related]
20. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]